David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 12,415 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75. Following the completion of the sale, the insider directly owned 871,737 shares of the company’s stock, valued at $8,760,956.85. This trade represents a 1.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

David Kirn also recently made the following trade(s):

• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.03, for a total transaction of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.87, for a total transaction of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $19,258.44.

4D Molecular Therapeutics Price Performance

FDMT traded up $0.18 during trading hours on Tuesday, reaching $10.27. 478,301 shares of the stock traded hands, compared to its average volume of 799,788. The firm’s fifty day simple moving average is $10.61 and its two-hundred day simple moving average is $9.68. The company has a market cap of $536.92 million, a price-to-earnings ratio of -4.00 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $5.23 and a fifty-two week high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. On average, research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.81 earnings per share for the current year.

Wall Street Analyst Weigh In

FDMT has been the topic of several recent analyst reports. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. B. Riley Financial initiated coverage on 4D Molecular Therapeutics in a research report on Friday. They issued a “buy” rating and a $37.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $30.67.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. raised its stake in shares of 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares in the last quarter. Janus Henderson Group PLC grew its stake in 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after purchasing an additional 611,276 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in 4D Molecular Therapeutics by 4.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock worth $32,272,000 after purchasing an additional 174,489 shares in the last quarter. State Street Corp increased its holdings in 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after buying an additional 1,785,106 shares during the last quarter. Finally, Armistice Capital LLC increased its holdings in 4D Molecular Therapeutics by 76.6% in the fourth quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after buying an additional 840,000 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.